Evidence map›Paper›PMID 33717971›Full record

ReviewJournal of clinical orthopaedics and trauma2021

Present and future scope of recombinant parathyroid hormone therapy in orthopaedics.

Arnab Sain, Hemant Bansal, Kirubakaran Pattabiraman, Vijay Sharma

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of clinical orthopaedics and trauma, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Romosozumab versus teriparatide and risk of all-cause mortality in patients with osteoporosis: a real-world propensity score-matched cohort study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026
    Article
  4. Article
  5. Review
  6. Article
  7. Timing of osteoporosis therapies following fracture: the current status.Therapeutic advances in endocrinology and metabolism · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Arnab SainDepartment of Orthopaedics, JPNATC, AIIMS, New Delhi, India.
Hemant BansalDepartment of Orthopaedics, JPNATC, AIIMS, New Delhi, India.
Kirubakaran PattabiramanDepartment of Orthopaedics, JPNATC, AIIMS, New Delhi, India.
Vijay SharmaDepartment of Orthopaedics, JPNATC, AIIMS, New Delhi, India.
All India Institute of Medical Sciences Raipur · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parathyroid Hormone (PTH) has a significant role in calcium metabolism. Its intermittent administration has an anabolic effect on bone mineralization. Teriparatide (PTH 1-34), a recombinant form of parathyroid hormone, is useful in the treatment of osteoporosis, fracture healing, non-union, stress fracture, augmentation of implant fixation with bone, and chondroprotection in osteoarthritis. The present review article will elaborate on the potential approved uses of recombinant PTH in orthopedics and its evolving role in the management of fracture osteosynthesis and other common challenging bone pathologies.

Indexed as

Fracture healingOsteonecrosisOsteoporosisParathyroid hormone (PTH)Stress fractureTeriparatide

Identifiers

PMID33717971
PMCPMC7920101
OpenAlexW3126790931

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.